Pharnext to Hold Its First Satellite Symposium "Focus on Charcot-Marie-Tooth Type 1A Disease" at the 23rd Neuromuscular Days in Marseille

Regulatory News:

Pharnext SA (Paris:ALPHA) (FR00111911287 - ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drugs based on the combination and repositioning of known drugs, today announced that it will hold its first Satellite Symposium "Focus on Charcot-Marie-Tooth Type 1A Disease" (CMT1A) on September 8th, 2017 at the 23^rd Neuromuscular Days (23èmes Journées Neuromusculaires) in Marseille, France.

Professor D. Adams, MD, PhD (Paris, France), will chair the session. Speakers are recognized leaders in the field of neurodenegerative diseases: Prof. S. Attarian, MD, PhD (Marseille, France) ; Prof. Y. Péréon, MD, PhD (Nantes, France) and Prof. L. Magy, MD, PhD (Limoges, France). Topics discussed by the faculty during this CMT1A-focused symposium will include: pathophysiology, clinical scales and natural history of the disease as well as new therapeutics in development and to come.

Details are as follows:

• Date: Friday, September 08, 2017
• Time: 08:30am to 09:30am CEST
• Location: La Major Room, 2^nd floor, Palais du Pharo, Marseille, France

For more information about the Pharnext symposium, please click here

About CMT1A
Charcot-Marie-Tooth (CMT) disease encompasses a heterogeneous group of inherited, progressive, chronic peripheral neuropathies. CMT type 1A (CMT1A), the most common type of CMT, is an orphan disease affecting at least 125,000 people in Europe and the U.S. The genetic mutation responsible for CMT1A is a duplication of the PMP22 gene coding for a peripheral myelin protein. Overexpression of this gene causes degradation of the neuronal sheath (myelin) responsible for nerve dysfunction, followed by loss of nerve conduction. As a result of peripheral nerve degradation, patients suffer from progressive muscle atrophy of their legs and arms causing walking, running, balance problems and abnormal hand functioning. CMT1A patients end up in wheelchairs in at least 5% of cases. Patients might also suffer from mild-to-moderate sensitive disorders. First symptoms usually appear during adolescence and progressively evolve through patients’ lives. To date, no curative or symptomatic medications have been approved and treatment consists of supportive care such as orthotics, leg braces, physical and occupational therapy or surgery.

About Pharnext
Pharnext is an advanced clinical-stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY™. The Company identifies and develops synergic combinations of repositioned drugs at new optimal lower doses. These PLEODRUG™ offer several key advantages: efficacy, safety and intellectual property including several product or composition of matter patents already granted. The Company is supported by a world-class scientific team.

The company Pharnext is listed on Euronext Growth Stock Exchange in Paris (ISIN code: FR00111911287).
For more information, visit www.pharnext.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20170831005809/en/